Adult Height in Patients with Congenital Adrenal Hyperplasia: A Systematic Review and Metaanalysis
The DOI matches its Crossref record; 58 of the 59 references it cites were found in a registry or an index.
Abstract
CONTEXT: Treatment for patients with congenital adrenal hyperplasia (CAH) may affect the final height of these patients. OBJECTIVE: Our objective was to determine the distribution of achieved height in patients with classic CAH diagnosed at infancy or early childhood and treated with glucocorticoids. DATA SOURCES: We searched MEDLINE, EMBASE, Cochrane Library, ISI Web of Science, and Scopus through September 2008; the reference sections of included studies; and expert files. STUDY SELECTION: Eligible studies included patients diagnosed with CAH before age 5 and followed to final height. DATA EXTRACTION: Reviewers working in duplicate independently extracted data on study characteristics and outcomes and determined each study's risk of bias. DATA SYNTHESIS: The sd score (SDS) for final height and corrected height (defined as final height SDS - midparental height SDS) were estimated from each study and pooled using random-effects metaanalysis. The I(2) statistic was used to assess inconsistency in results across studies. RESULTS: We found 35 eligible studies, most of which were retrospective single-cohort studies. The final height SDS achieved by CAH patients was -1.38 (-1.56 to -1.20; I(2) = 90.2%), and the corrected height SDS was -1.03 (-1.20 to -0.86; I(2) = 63.1%). This was not significantly associated with age at diagnosis, gender, type and dose of steroid, and age of onset of puberty. Mineralocorticoid users had a better height outcome in comparison with the nonusers (P = 0.02). CONCLUSION: Evidence derived from observational studies suggests that the final height of CAH patients treated with glucocorticoids is lower than the population norm and is lower than expected given parental height.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“A meta-analysis of adult height in classic CAH found that mineralocorticoid therapy during childhood was associated with a higher height outcome compared with those who did not receive mineralocorticoid therapy.6”
From Congenital adrenal hyperplasia complicated by gonadotropin-dependent precocious puberty (2024) · cites this paper as [6]
In the citing paper
“A systematic review and meta-analysis for >1000 classic CAH patients found shorter than average stature for mid-parental heights (-1.03 standard deviations, corresponding to ~7 cm) (33), but many of these children were diagnosed before the implementation of neonatal screening and did not receive the benefit of early initiation of treatment.”
From Congenital Adrenal Hyperplasia—Current Insights in Pathophysiology, Diagnostics, and Management (2022) · cites this paper as [33]
In the citing paper
“A meta-analysis of adult height in classic CAH found that mineralocorticoid therapy during childhood was associated with a taller height outcome compared with those who did not receive mineralocorticoid therapy38.”
From Management challenges and therapeutic advances in congenital adrenal hyperplasia (2022) · cites this paper as [38]
In the citing paper
“A meta-analysis of >1,000 patients with classic CAH found shorter than average adult height when adjusted for genetic potential (–1.03 standard deviation below expected height based on parental heights, ~7 cm)38.”
From Management challenges and therapeutic advances in congenital adrenal hyperplasia (2022) · cites this paper as [38]
In the citing paper
“Maintaining sodium balance is essential for euvolemia and for reducing vasopressin and ACTH, allowing reduced GC doses and thus leading to better growth (186).”
From Congenital Adrenal Hyperplasia Due to Steroid 21-Hydroxylase Deficiency: An Endocrine Society* Clinical Practice Guideline (2018) · cites this paper as [186]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & for the PRISMA Group (2009) · BMJ · doi:10.1136/bmj.b2535 · Cited by 83,823
Measuring inconsistency in meta-analyses
Higgins, J. P. T., Thompson, S. G., Deeks, J. J., & Altman, D. G. (2003) · BMJ · doi:10.1136/bmj.327.7414.557 · Cited by 63,139 · cited 1×
“This statistic explains the proportion of inconsistency between studies that cannot be explained by chance alone and is likely due to real differences in the population or the conduct of the studies (15).”
BackgroundPreferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement.
(2009) · PubMed Central · Cited by 44,859
Meta-analysis in clinical trials
DerSimonian, R., & Laird, N. (1986) · Controlled Clinical Trials · doi:10.1016/0197-2456(86)90046-2 · Cited by 39,552 · cited 4×
“Height in Patients with CAH J Clin Endocrinol Metab, September 2010, 95(9):4161–4172”
BackgroundMethodInfluentialPreferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
Moher, D., Liberati, A., Tetzlaff, J., & Altman, D. G. (2009) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2009.06.005 · Cited by 19,575
Interaction revisited: the difference between two estimates.
Altman, D. G., & Bland, J. M. (2003) · BMJ · doi:10.1136/bmj.326.7382.219 · Cited by 3,203 · cited 1×
“We tested for subgroup-height interactions (16) con4162 Muthusamy et al.”
Speiser, P. W., Azziz, R., Baskin, L. S., Ghizzoni, L., Hensle, T. W., Merke, D. P., Meyer-Bahlburg, H. F. L., Miller, W. L., Montori, V. M., Oberfield, S. E., et al. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-2631 · Cited by 1,468
Self-citationStandards for Children's Height at Ages 2-9 Years Allowing for Height of Parents
Tanner, J. M., Goldstein, H., & Whitehouse, R. H. (1970) · Archives of Disease in Childhood · doi:10.1136/adc.45.244.755 · Cited by 812
Therrell, B. L., Berenbaum, S. A., Manter-Kapanke, V., Simmank, J., Korman, K., Prentice, L., Gonzalez, J., & Gunn, S. (1998) · Pediatrics · doi:10.1542/peds.101.4.583 · Cited by 344 · cited 1×
“This condition has a worldwide incidence of approximately one in 15,000 births (1, 2).”
BackgroundSwiglo, B. A., Murad, M. H., Schünemann, H. J., Kunz, R., Vigersky, R. A., Guyatt, G. H., & Montori, V. M. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-1907 · Cited by 302 · cited 1×
“We consider the quality of evidence very low (31) due to the serious methodological limitations of included studies, large inconsistency of results across studies, and unclear importance of the outcome.”
BackgroundSelf-citationPatient-Important Outcomes in Registered Diabetes Trials
Gandhi, G. Y. (2008) · JAMA · doi:10.1001/jama.299.21.2543 · Cited by 252
Eugster, E. A., DiMeglio, L. A., Wright, J. C., Freidenberg, G. R., Seshadri, R., & Pescovitz, O. H. (2001) · The Journal of Pediatrics · doi:10.1067/mpd.2001.110527 · Cited by 197 · cited 1×
“A metaanalysis summarizing data accumulated up to1998 (6) identified 18 eligible studies and concluded that the impact of treated CAH on height achieved was small to moderate ( 1.”
BackgroundBonfig, W., Bechtold, S., Schmidt, H., Knorr, D., & Schwarz, H. P. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-2109 · Cited by 167
Klingensmith, G. J., Garcia, S. C., Jones, H. W., Migeon, C. J., & Blizzard, R. M. (1977) · The Journal of Pediatrics · doi:10.1016/s0022-3476(77)80581-7 · Cited by 163
Jääskeläinen, J., & Voutilainen, R. (1997) · Pediatric Research · doi:10.1203/00006450-199701000-00005 · Cited by 160
Stikkelbroeck, N. M. M. L., Oyen, W. J. G., van der Wilt, G.-J., Hermus, A. R. M. M., & Otten, B. J. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-021074 · Cited by 138
Bonfig, W., Dalla Pozza, S. B., Schmidt, H., Pagel, P., Knorr, D., & Schwarz, H. P. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-0942 · Cited by 136 · cited 1×
“A recent study (32) recommended that the dose of hydrocortisone should not exceed 17 mg/m(2) d to optimize pubertal growth.”
BackgroundLonger term outcome in females with congenital adrenal hyperplasia (CAH): the Cardiff experience
Premawardhana, L. D. K. E., Hughes, I. A., Read, G. F., & Scanlon, M. F. (1997) · Clinical Endocrinology · doi:10.1046/j.1365-2265.1997.1360962.x · Cited by 135 · cited 1×
“The same was true for corrected height SDS after the exclusion of three studies in which the mean parental height was used instead of midparental height (3, 19, 29) and a study in which a correction factor was added to the midparental height to account for the secular trend in the population (20).”
Bone mineral density and body composition in congenital adrenal hyperplasia.
Cameron, F. J., Kaymakci, B., Byrt, E. A., Ebeling, P. R., Warne, G. L., & Wark, J. D. (1995) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.80.7.7608286 · Cited by 114
Lin-Su, K., Vogiatzi, M. G., Marshall, I., Harbison, M. D., Macapagal, M. C., Betensky, B., Tansil, S., & New, M. I. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-2128 · Cited by 111
(1988) · PubMed · Cited by 110
Longitudinal analysis of growth and puberty in 21-hydroxylase deficiency patients
Van der Kamp, H. J. (2002) · Archives of Disease in Childhood · doi:10.1136/adc.87.2.139 · Cited by 104
Balsamo, A., Cicognani, A., Baldazzi, L., Barbaro, M., Baronio, F., Gennari, M., Bal, M., Cassio, A., Kontaxaki, K., & Cacciari, E. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-030123 · Cited by 102 · cited 1×
“One author also provided data on two additional patients included in the cohort since the publication of the study (17).”
BackgroundPinto, G., Tardy, V., Trivin, C., Thalassinos, C., Lortat-Jacob, S., Nihoul-Fékété, C., Morel, Y., & Brauner, R. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-021433 · Cited by 101
Manoli, I., Kanaka‐Gantenbein, C., Voutetakis, A., Maniati‐Christidi, M., & Dacou‐Voutetakis, C. (2002) · Clinical Endocrinology · doi:10.1046/j.1365-2265.2002.01645.x · Cited by 100 · cited 2×
“Comparison with other reviews Final adult height is influenced by many factors, namely age at diagnosis (38), dose of glucocorticoid therapy (39), adequacy of treatment (13), and form of CAH (25).”
BackgroundQuintos, J. B. Q., Vogiatzi, M. G., Harbison, M. D., & New, M. I. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.4.7412 · Cited by 96
Jääskeläinen, J., & Voutilainen, R. (1996) · Clinical Endocrinology · doi:10.1046/j.1365-2265.1996.8620871.x · Cited by 92
Height and Social Adjustment: Are Extremes a Cause for Concern and Action?
Sandberg, D. E., Bukowski, W. M., Fung, C. M., & Noll, R. B. (2004) · PEDIATRICS · doi:10.1542/peds.2003-1169-l · Cited by 86
Sciannamblo, M., Russo, G., Cuccato, D., Chiumello, G., & Mora, S. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-2823 · Cited by 82
Quintos, J. B. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.86.4.1511 · Cited by 80
Soliman, A. T., Al-Lamki, M. A., Salmi, I. A., & Asfour, M. G. (1997) · Metabolism · doi:10.1016/s0026-0495(97)90186-4 · Cited by 78
The effect of treatment of final height in classical congenital adrenal hyperplasia (CAH)
DiMartino-Nardi, J., Stoner, E., O'Connell, A., & New, M. I. (1986) · Acta Endocrinologica · doi:10.1530/acta.0.112s305 · Cited by 77
Hargitai, G., Sólyom, J., Battelino, T., Lebl, J., Pribilincová, Z., Hauspie, R., Kovács, J., Waldhauser, F., & Frisch, H. (2001) · Hormone Research in Paediatrics · doi:10.1159/000049990 · Cited by 76
Muirhead, S. E., Sellers, E. A. C., & Guyda, H. J. (2002) · The Journal of Pediatrics · doi:10.1067/mpd.2002.126601 · Cited by 62 · cited 2×
“The same was true for corrected height SDS after the exclusion of three studies in which the mean parental height was used instead of midparental height (3, 19, 29) and a study in which a correction factor was added to the midparental height to account for the secular trend in the population (20).”
BackgroundGrowth and body proportions in congenital adrenal hyperplasia.
Young, M. C., Ribeiro, J., & Hughes, I. A. (1989) · Archives of Disease in Childhood · doi:10.1136/adc.64.11.1554 · Cited by 55
The Effect of Therapy on Mature Height in Congenital Adrenal Hyperplasia*
KIRKLAND, R. T., KEENAN, B. S., HOLCOMBE, J. H., KIRKLAND, J. L., & CLAYTON, G. W. (1978) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-47-6-1320 · Cited by 52 · cited 1×
“Comparison with other reviews Final adult height is influenced by many factors, namely age at diagnosis (38), dose of glucocorticoid therapy (39), adequacy of treatment (13), and form of CAH (25).”
BackgroundYu, A., & Grant, D. (1995) · Acta Paediatrica · doi:10.1111/j.1651-2227.1995.tb13789.x · Cited by 52
Congenital adrenal hyperplasia
Conway, G. S., & Mouriquand, P. D. E. (2004) · Paediatric and Adolescent Gynaecology · doi:10.1017/cbo9780511527036.025 · Cited by 48
Adrenal 21‐hydroxylase deficiency in childhood: 25 years' experience
LIM, Y. J., BATCH, J. A., & WARNE, G. L. (1995) · Journal of Paediatrics and Child Health · doi:10.1111/j.1440-1754.1995.tb00790.x · Cited by 43 · cited 1×
“The same was true for corrected height SDS after the exclusion of three studies in which the mean parental height was used instead of midparental height (3, 19, 29) and a study in which a correction factor was added to the midparental height to account for the secular trend in the population (20).”
Grigorescu-Sido, A., Bettendorf, M., Schulze, E., Duncea, I., & Heinrich, U. (2003) · Hormone Research in Paediatrics · doi:10.1159/000071876 · Cited by 42 · cited 1×
“Comparison with other reviews Final adult height is influenced by many factors, namely age at diagnosis (38), dose of glucocorticoid therapy (39), adequacy of treatment (13), and form of CAH (25).”
BackgroundGrowth in Congenital Adrenal Hyperplasia
BERGSTRAND, C. G. (1966) · Acta Paediatrica · doi:10.1111/j.1651-2227.1966.tb15237.x · Cited by 41
Evaluation of Young Women with Congenital Adrenal Hyperplasia: A Pilot Study
van der Kamp, H. J., Slijper, F. M. E., Brandenburg, H., Keizer-Schrama, D. M., Drop, S., & Molenaar, J. (1992) · Hormone Research · doi:10.1159/000182400 · Cited by 37 · cited 1×
“The same was true for corrected height SDS after the exclusion of three studies in which the mean parental height was used instead of midparental height (3, 19, 29) and a study in which a correction factor was added to the midparental height to account for the secular trend in the population (20).”
Hoepffner, W., Kaufhold, A., Willgerodt, H., & Keller, E. (2008) · Hormone Research in Paediatrics · doi:10.1159/000129677 · Cited by 34
[Final height in 69 patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiency].
David, M., Sempe, M., Blanc, M., Nicolino, M. P., Forest, M., & Morel, Y. (1994) · PubMed · Cited by 32
Nimkarn, S., New, M. I., & Lin-Su, K. (2007) · Journal of Pediatric Endocrinology and Metabolism · doi:10.1515/jpem.2007.20.8.883 · Cited by 29
THE EFFECT OF TREATMENT ON FINAL HEIGHT IN CLASSICAL CONGENITAL ADRENAL HYPERPLASIA (CAH)
DiMartino-Nardi, J., Stoner, E., & O'Connell, A. (1986) · Pediatric Research · doi:10.1203/00006450-198611000-00168 · Cited by 18
Aycan, Z., Öçal, G., Berberoğlu, M., Çetinkaya, E., Adıyaman, P., & Evliyaoğlu, O. (2006) · Journal of Pediatric Endocrinology and Metabolism · doi:10.1515/jpem.2006.19.3.245 · Cited by 18
The cse in support of GH therapy
Saenger, P. H. (2000) · The Journal of Pediatrics · doi:10.1016/s0022-3476(00)90059-3 · Cited by 17 · cited 1×
“The psychological impact on the child of treating short stature as a disease has been questioned (35), and our society’s aspiration for perfection can be seen as the driving force for the temptation to treat (36).”
BackgroundUnresolved problems in the treatment of congenital adrenal hyperplasia.
Tanae, A., & Hibi, I. (1988) · PubMed · Cited by 13
Pasqualini, T., Alonso, G., Tomasini, R., Galich, A. M., Buzzalino, N. D., Fernández, C. S., Minutolo, C., Alba, L. G., & Daín, L. (2007) · PubMed · Cited by 12
Gussinyé, M., Potau, N., Vicens-Calvet, E., Ma, A., Yeste, D., Ibáñez, L., Audı́, L., & Carrascosa, A. (1997) · PubMed · Cited by 12
de Lemos‐Marini, S. H. V., Guerra‐Júnior, G., Morcillo, A. M., Baptista, M. T. M., Silva, L. O., & Maciel‐Guerra, A. T. (2005) · Arquivos Brasileiros de Endocrinologia & Metabologia · doi:10.1590/s0004-27302005000600008 · Cited by 10
17‐Hydroxyprogesterone rhythms and growth velocity in congenital adrenal hyperplasia
PINCUS, D. R., Kelnar, C. J. H., & Wallace, A. M. (1993) · Journal of Paediatrics and Child Health · doi:10.1111/j.1440-1754.1993.tb00517.x · Cited by 9 · cited 1×
“androstenedione, testosterone (3), and 17-OH progesterone (4)] and adjust medical therapy to achieve age-appropriate bone age and linear growth.”
BackgroundToo tall, too small? The temptation to tinker with a child's height
Cohen, S., & Cosgrove, C. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60185-7 · Cited by 7 · cited 1×
“The psychological impact on the child of treating short stature as a disease has been questioned (35), and our society’s aspiration for perfection can be seen as the driving force for the temptation to treat (36).”
Background[Growth and adult height in patients with congenital adrenal hyperplasia].
Koloušková, S., Zemkova, D., Šnajderová, M., & Lebl, J. (1995) · PubMed · Cited by 7
[Growth and puberal development in males with adreno-genital syndrome].
Gargantini, L., Calzi, P., Brunelli, Braggion, F., & Chiumello, G. (1989) · PubMed · Cited by 6
Growth pattern and final height in 21-hydroxylase deficiency.
Bajpai, A., Pandey, R. M., Kabra, M., & Menon, P. S. N. (2007) · PubMed · Cited by 5
Gschwend, S., & Lee, P. A. (1993) · Journal of Pediatric and Adolescent Gynecology · doi:10.1016/s0932-8610(12)80045-4 · Cited by 2
Cited by
Speiser, P. W., Azziz, R., Baskin, L. S., Ghizzoni, L., Hensle, T. W., Merke, D. P., Meyer-Bahlburg, H. F. L., Miller, W. L., Montori, V. M., Oberfield, S. E., et al. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-2631 · Cited by 1,468
“for reducing vasopressin andACTH, allowing reducedGC doses and thus leading to better growth (186).”
BackgroundSelf-citationSpeiser, P. W., Arlt, W., Auchus, R. J., Baskin, L. S., Conway, G. S., Merke, D. P., Meyer-Bahlburg, H. F. L., Miller, W. L., Murad, M. H., Oberfield, S. E., et al. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-01865 · Cited by 1,234
Self-citationCongenital adrenal hyperplasia
El-Maouche, D., Arlt, W., & Merke, D. P. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31431-9 · Cited by 669
Congenital Adrenal Hyperplasia—Current Insights in Pathophysiology, Diagnostics, and Management
Claahsen - van der Grinten, H. L., Speiser, P. W., Ahmed, S. F., Arlt, W., Auchus, R. J., Falhammar, H., Flück, C. E., Guasti, L., Huebner, A., Kortmann, B. B. M., et al. (2022) · Endocrine Reviews · doi:10.1210/endrev/bnab016 · Cited by 556
Congenital adrenal hyperplasia due to 21-hydroxylase deficiency
Merke, D. P., & Auchus, R. J. (2020) · New England Journal of Medicine · doi:10.1056/nejmra1909786 · Cited by 341
Metadata
- Authors
- Muthusamy, K., Elamin, M. B., Smushkin, G., Murad, M. H., Lampropulos, J. F., Elamin, K. B., Abu Elnour, N. O., Gallegos-Orozco, J. F., Fatourechi, M. M., Agrwal, N., Lane, M. A., Albuquerque, F. N., Erwin, P. J., & Montori, V. M.
- Affiliations
- Mayo Clinic (US)
- St. Luke's General Hospital (IE)
- ORCID
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2010-09
- Volume
- 95
- Issue
- 9
- Pages
- 4161-4172
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2076225993
- Cited by
- 182
- References
- 59
- Citations by year
- 2026: 11 · 2025: 20 · 2024: 20 · 2023: 16 · 2022: 12 · 2021: 12 · 2020: 8 · 2019: 10 · 2018: 4 · 2017: 7 · 2016: 9 · 2015: 8 · 2014: 9 · 2013: 12 · 2012: 11
- FWCI
- 1.01
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Sexual Differentiation and Disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
- Health Sciences › Medicine › Reproductive Medicine › Ovarian function and disorders
- Keywords
- congenital adrenal hyperplasia, adult height, glucocorticoid therapy, mineralocorticoids, growth hormone, age at diagnosis, puberty onset, mid-parental height, height SDS
- MeSH terms
- Adrenal Hyperplasia, Congenital, Adult, Algorithms, Body Height, Glucocorticoids, Growth Disorders, Humans, Mineralocorticoids, Treatment Outcome, Human Growth Hormone
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.